IWILFIN (eflornithine)
High-risk neuroblastoma (relapse prevention)
ApprovedActive
Key Facts
About US WorldMeds
Founded in 2001 and headquartered in Louisville, Kentucky, US WorldMeds is a commercial-stage, private specialty pharma company. It operates a business model centered on in-licensing and developing small molecule therapeutics for rare and challenging diseases, particularly in oncology. The company achieved a significant milestone in December 2023 with the FDA approval of IWILFIN™ (eflornithine) for high-risk neuroblastoma, demonstrating its capability to bring novel treatments to market. Its pipeline and portfolio appear focused on niche therapeutic areas with limited treatment options.
View full company profile